Abstract: The present invention provides antibodies which bind to the Delta/Serrate/LAG-2 consensus sequence (DSL) domain of human Jagged 1 via novel epitopes comprising the residue E228, and inhibit the interaction between human Jagged 1 and its associated receptors. Said antibodies may be administered therapeutically in the treatment of tumors/cancer, preferably those associated with tumoral Jagged 1-mediated signalling and tumor microenvironmental processes in which Jagged 1 and/or Notch-mediated signalling has been implicated, including those comprising Jagged 1-mediated cross talk between the tumor and the tumor microenvironment. The present invention also provides pharmaceutical compositions comprising said antibodies, uses of said antibodies in therapy, hybridomas comprising and/or secreting said antibodies and cells or cell lines expressing said antibodies and humanized/deimmunized variants in recombinant form.

Abstract: The invention relates to polypeptides, and in particular to polypeptides that are capable of inhibiting the activity or activation of the complement system. It also relates to nucleic acids that encode the polypeptides and to uses of the polypeptides. The complement system helps or “complements” the ability of antibodies and phagocytic cells to clear pathogens from an organism. It forms part of the innate immune system. Down-regulation of complement activation has been demonstrated to be effective in treating several disease indications in animal models and in ex vivo studies. The present invention provides novel polypeptides that can be used for the treatment of diseases or disorders that relate to inappropriate activation of one or more of the complement pathways.

Abstract: The present invention provides antibodies which bind to the Delta/Serrate/LAG-2 consensus sequence (DSL) domain of human Jagged 1 via novel epitopes comprising the residue E228, and inhibit the interaction between human Jagged 1 and its associated receptors. Said antibodies may be administered therapeutically in the treatment of tumours/cancer, preferably those associated with tumoural Jagged 1-mediated signalling and tumour microenvironmental processes in which Jagged 1 and/or Notch-mediated signalling has been implicated, including those comprising Jagged 1-mediated cross talk between the tumour and the tumour microenvironment. The present invention also provides pharmaceutical compositions comprising said antibodies, uses of said antibodies in therapy, hybridomas comprising and/or secreting said antibodies and cells or cell lines expressing said antibodies and humanised/deimmunised variants in recombinant form.

Abstract: The present invention provides an immunogenic composition capable of eliciting an immune response when administered to a human or non-human animal, wherein the composition comprises an isolated protein with one or more of the following properties: i) about 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or more percent sequence identity to the protein of SEQ ID No: 1 or a fragment, derivative or analog thereof; ii) is a modified factor H binding protein, wherein the factor H binding protein has been modified at least at the position equivalent to position 318 as defined in FIG. 6 (SEQ ID No: 2); iii) does not bind to factor H; and iv) the immune response elicited is cross reactive with two or more of variant 1 factor H binding protein, variant 2 factor H binding protein and variant 3 factor H binding protein from N. meningitidis; and uses thereof.